News
In the last two decades, it has become clear that γδ T cells recognize a diverse array of antigens including self and foreign, large and small, and peptidic and non-peptidic molecules. In this ...
Linsley, P. S. et al. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl Acad. Sci. USA 87, 5031–5035 (1990).. Linsley, P. S. et al ...
However, these cells enhance the immune response to HEL when it behaves as a foreign antigen in wild-type mice. 17 Thus, these Qa1-dependent CD8+ T cells participate both in the development of ...
9mon
News-Medical.Net on MSNDietary antigens reduce small intestine cancer by boosting immune T-cellsBy Pooja Toshniwal Paharia New research reveals how common dietary proteins like bovine serum albumin (BSA) or ovalbumin (OVA ...
Characterization of antigen-specific T cell responses typically is a critical constituent of these immunological investigations which can also aid in patient stratification for future trials. As a ...
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the ...
14d
News-Medical.Net on MSNStudy unveils powerful strategy to rejuvenate effectiveness of CAR T cell therapy against glioblastomaA team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers ...
Researchers from Shanghai Institute of Biological Products Co. Ltd. published details on the development and preclinical characterization of novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 ...
These CAR-T cells showed antigen-dependent activation, effectively killing GUCY2C-expressing cancer cells in vitro and providing long-term protection in mouse models against lung metastases of CRC. 39 ...
Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and predicts that a treatment could be approved in the next 5-10 years.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results